Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Year : 1995  |  Volume : 16  |  Issue : 2  |  Page : 133-135

Chemotherapy in ovarian cancer experience at railway cancer institute varanasi.

Indian Railway Cancer Institute & Research Centre, Varanasi-221002, India

Correspondence Address:
RC Joshi
Indian Railway Cancer Institute & Research Centre, Varanasi-221002, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Ovarian cancer is the third most common cancer among women. We have seen 53 patients with ovarian tumour over four years period. Thirty four(63 percent) patients had FIGO stage III and IV disease. Histopathology subtypes were: epithelial cancer in 89 percent and germ cell tumour of ovary in 11 percent of patients. 35 of 53 patients received cisplatin, cyclophosphamide and doxorubicin(CAP, n=12) or cisplatin and cyclophosphamide(CP,n=9)and cisplatin, bleomycin and vinblastine(PVB, n=2). Twenty three patients were evaluable for response. Twenty patients achieved significant response; complete 13(56 percent) and partial response in 7(30 percent) patients. Nausea/vomiting, alopecia were the main side effects due to chemotherapy. Currently, seven patients are alive, disease-free at a median follow up of 2 years(1-3 years). A longer follow up is required to see the impact of chemotherapy on overall and disease-free survival.

[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal